2017 Half-Year Results
Solid cash position of €20 million
and significant scientific progress
Toulouse, FRANCE, Lakeland, UNITED STATES, September 12, 2017 – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of innovative therapies based on lipid metabolism for treating cardiovascular and metabolic diseases, today announces its results for the first half of 2017.
Please find attached the complete PDF file.
| About Cerenis Therapeutics |
| Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids is removed from arteries and is transported to the liver for elimination from the body.
Cerenis is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development. |
| Cerenis Jean-Louis Dasseux CEO Phone nb.: 05 62 24 09 49 Email: info@cerenis.com |
NewCap Emmanuel Huynh / Louis-Victor Delouvrier Investor relations Phone nb.: 01 44 71 98 53 Email: cerenis@newcap.eu |
NewCap Nicolas Merigeau Media Relations Phone nb.: 01 44 71 94 98 Email: cerenis@newcap.eu |
Source: Cerenis
